List of monoclonal antibodies

This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see “Nomenclature of monoclonal antibodies“).

Name	Target	Source
Abagovomab	go(v)	o
Abciximab	ci(r)	xi
Adalimumab	li(m)	u
Adecatumumab	tu(m)	u
Afelimomab	li(m)	o
Alemtuzumab	tu(m)	zu
Altumomab	tu(m)	o
Ananeuzumab	neu(r)	zu
Anatumomab mafenatox	tu(m)	o
Anergrozumab	?	zu
Anetumumab	tu(m)	u
Anrulizumab	li(m)	zu
Apolizumab	li(m)	zu
Arcitumomab	tu(m)	o
Aselizumab	li(m)	zu
Atlizumab	li(m)	zu
Atorolimumab	li(m)	u
Azulizumab	li(m)	zu
Balizumab	li(m)	zu
Bapineuzumab	neu(r)	zu
Basiliximab	li(m)	xi
Bavituximab	tu(m)	xi
Bectumomab	tu(m)	o
Belimumab	li(m)	u
Belizumab	li(m)	zu
Bertilimumab	li(m)	u
Besilesomab	le(s)	o
Betumumab	tu(m)	u
Bevacizumab	ci(r)	zu
Biciromab brallobarbital	ci(r)	o
Bivatuzumab mertansine	tu(m)	zu
Campath – Redirects to alemtuzumab	tu(m)	zu
Canakinumab	ki(n)	u
Cantuzumab mertansine	tu(m)	zu
Capromab	pr(o)	o
Catumaxomab	tu(m)	axo
Cedelizumab	li(m)	zu
Certolizumab pegol	li(m)	zu
Cetforlimumab	li(m)	u
Cetinlimumab	li(m)	u
Cetlalimumab	li(m)	u
Cetolimumab	li(m)	u
Cetuximab	tu(m)	xi
Cidfusituzumab	tu(m)	zu
Cidtuzumab	tu(m)	zu
Citilimumab	li(m)	u
Clenoliximab	li(m)	xi
Cynosumab	o(s)	u
Cynotumumab – Redirects to cynosumab	o(s)	u
Dacetuzumab	tu(m)	zu
Dacliximab – Redirects to daclizumab	li(m)	zu
Daclizumab	li(m)	zu
Denosumab	o(s)	u
Denotumumab – Redirects to denosumab	o(s)	u
Destilimumab	li(m)	u
Detumomab	tu(m)	o
Doraglizumab	li(m)	zu
Dorlimomab aritox	li(m)	o
Dorlixizumab	li(m)	xizu
Dorlizumab	li(m)	zu
Drinalizumab	li(m)	zu
Duntumumab	tu(m)	u
Durimulumab	mu(l)	u
Durlizumab	li(m)	zu
Durmulumab	mu(l)	u
Ecromeximab	me(l)	xi
Eculizumab	li(m)	zu
Edobacomab	ba(c)	o
Edrecolomab	co(l)	o
Efalizumab	li(m)	zu
Efungumab	fu(ng)	u
Elsilimomab	li(m)	o
Enlimomab pegol	li(m)	o
Enlimomab	li(m)	o
Epitumomab cituxetan	tu(m)	o
Epitumomab	tu(m)	o
Epkizumab	ki(n)	zu
Epratuzumab	tu(m)	zu
Erlizumab	li(m)	zu
Ertumaxomab	tu(m)	axo
Etaracizumab	ci(r)	zu
Etaratuzumab	tu(m)	zu
Exbivirumab	vi(r)	u
Extumumab	tu(m)	u
Efalizumab	li(m)	zu
Fanolesomab	le(s)	o
Faralimomab	li(m)	o
Felvizumab	vi(r)	zu
Fontolizumab	li(m)	zu
Futumumab	tu(m)	u
Galiximab	li(m)	xi
Gantenerumab	?	u
Gavilimomab	li(m)	o
Gemtuzumab ozogamicin	tu(m)	zu
Genosumab	o(s)	u
Golimumab	li(m)	u
Gomiliximab	li(m)	xi
Hylizumab	li(m)	zu
Ibalizumab	li(m)	zu
Ibritumomab tiuxetan	tu(m)	o
Igovomab	go(v)	o
Imciromab	ci(r)	o
Infliximab	li(m)	xi
Inolimomab	li(m)	o
Inotuzumab ozogamicin	tu(m)	zu
Intumumab	tu(m)	u
Ipilimumab	li(m)	u
Iratumumab	tu(m)	u
Keliximab	li(m)	xi
Labetuzumab	tu(m)	zu
Lemalesomab	le(s)	o
Lebrilizumab	li(m)	zu
Lerdelimumab	li(m)	u
Lexatumumab	tu(m)	u
Lexitumumab	tu(m)	u
Libivirumab	vi(r)	u
Lintuzumab	tu(m)	zu
Lucalizumab	li(m)	zu
Lucatumumab	tu(m)	u
Lumiliximab	li(m)	xi
Mapatumumab	tu(m)	u
Maslimomab	li(m)	o
Matenazumab	?	zu
Matuzumab	tu(m)	zu
Mepolizumab	li(m)	zu
Metelimumab	li(m)	u
Minretumomab	tu(m)	o
Mitumomab	tu(m)	o
Morolimumab	li(m)	u
Motavizumab	vi(r)	zu
Muromonab-CD3 monoclonal antibody	?	o
Nacolomab tafenatox	co(l)	o
Naptumomab estafenatox	tu(m)	o
Natalizumab	li(m)	zu
Nebacumab	ba(c)	u
Nerelimomab	li(m)	o
Nimotuzumab	tu(m)	zu
Nofetumomab merpentan	tu(m)	o
Nolovizumab	vi(r)	zu
Numavizumab	vi(r)	zu
Ocrelizumab	li(m)	zu
Odulimomab	li(m)	o
Ofatumumab	tu(m)	u
Omalizumab	li(m)	zu
Oregovomab	go(v)	o
Oteliximab	li(m)	xi
Otelixizumab	li(m)	xizu
Pagibaximab	ba(c)	xi
Palivizumab	vi(r)	zu
Panitumumab	tu(m)	u
Pascolizumab	li(m)	zu
Pecfusituzumab	tu(m)	zu
Pectuzumab	tu(m)	zu
Pemtumomab	tu(m)	o
Pertuzumab	tu(m)	zu
Pexelizumab	li(m)	zu
Pintumomab	tu(m)	o
Priliximab	li(m)	xi
Pritumumab	tu(m)	u
Quartuzumab	tu(m)	zu
Quetumumab	tu(m)	u
Ralivizumab	vi(r)	zu
Ranibizumab	?	zu
Raxibacumab	ba(c)	u
Regavirumab	vi(r)	u
Resatumumab	tu(m)	u
Restumumab	tu(m)	u
Reslivizumab	vi(r)	zu
Reslizumab	li(m)	zu
Resyvizumab	vi(r)	zu
Rilotumumab	tu(m)	u
Rituximab	tu(m)	xi
Rosutumumab	tu(m)	u
Rovelizumab	li(m)	zu
Ruplizumab	li(m)	zu
Satumomab	tu(m)	o
Sevirumab	vi(r)	u
Sibrotuzumab	tu(m)	zu
Siplizumab	li(m)	zu
Sontuzumab	tu(m)	zu
Stamulumab	mu(l)	u
Sulesomab	le(s)	o
Synosumab	o(s)	u
Tacatuzumab tetraxetan	tu(m)	zu
Tadocizumab	ci(r)	zu
Talineuzumab	neu(r)	zu
Talizumab	li(m)	zu
Taneuzumab	neu(r)	zu
Tanirazumab	?	zu
Taplitumomab paptox	tu(m)	o
Tefibazumab	ba(c)	zu
Teglizumab	li(m)	zu
Telimomab aritox	li(m)	o
Teneliximab	li(m)	xi
Teplizumab	li(m)	zu
Ticilimumab – Redirects to tremelimumab	li(m)	u
Tiratumumab	tu(m)	u
Tocilizumab	li(m)	zu
Tolizumab	li(m)	zu
Toralizumab	li(m)	zu
Tositumomab	tu(m)	o
Tralizumab	li(m)	zu
Trastuzumab	tu(m)	zu
Treglizumab	li(m)	zu
Trelizumab	li(m)	zu
Tremelimumab	li(m)	u
Trilizumab	li(m)	zu
Tritumumab	tu(m)	u
Trixatumumab	tu(m)	u
Tucotuzumab celmoleukin	tu(m)	zu
Tucusituzumab	tu(m)	zu
Tuvirumab	vi(r)	u
Ubrelizumab	li(m)	zu
Umavizumab	vi(r)	zu
Urtoxazumab	tox(a)	zu
Valtumumab	tu(m)	u
Vapaliximab	li(m)	xi
Vepalimomab	li(m)	o
Vexatumumab	tu(m)	u
Visilizumab	li(m)	zu
Volociximab	ci(r)	xi
Votumumab	tu(m)	u
Xalizumab	li(m)	zu
Zalutumumab	tu(m)	u
Zanolimumab	li(m)	u
Ziralimumab	li(m)	u
Zolimomab aritox	li(m)	o
Zulizumab	li(m)	zu